For companies in the biopharmaceutical industry, the stakes are always high, and the odds are always long. That’s particularly the case when it comes to drug discovery. Today, 97 percent of all drug discovery programs fail, and the cost of developing a new therapeutic averages $2.6 billion, according to Frost & Sullivan.1
The challenges don’t stop there. Biopharma companies are wrestling with enormous and ever-growing amounts of data stemming from genomics research — data that is doubling every seven months, according to TATA Consultancy Services.2 All the while, regulatory requirements are becoming more onerous and more costly with each passing year.